Hemab Therapeutics Holdings, Inc. COAG
49.02 USD +3.45 (+7.57%)
At closeNov 6, 2026, 4:00 PM EST
49.02 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
45.52 Day range 49.12
24.98 52-week range 54.94
- YTD
- +44.18%
- 1 year
- +44.18%
- Market cap
- 2.29B
- EPS (ttm)
- -4.33
- Shares out
- 46.71M
- Forward P/E
- -19.25
- YTD return
- +44.18%
- 1-year return
- +44.18%
- Volume
- 427.95K
- Avg volume
- 458.33K
- Open
- 46.18
- Previous close
- 45.57
- Day's range
- 45.52 – 49.12
- 52-week range
- 24.98 – 54.94
- Price target
- 62.67 (+27.8%)
- Earnings date
- Nov 10, 2026
ALL +15.02 (+44.18%)
Key statistics
- Enterprise value
- 1.67B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 457.46M
- Total debt
- 1.03M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 37.51
- 200-day average
- 36.99
Analyst view
Price target (mean) 62.67 +27.8% upside
Now 49.02
- Target (low)
- 58.00
- Target (mean)
- 62.67
- Target (high)
- 70.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -0.51529.
Financials — quick view
COAG Revenue — quarterly 0
COAG Net income — quarterly -24.15M
COAG EPS — quarterly -0.80
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | -0.50194 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.7325 | -0.80 | -0.07 | -9.22% |
| May 21, 2026 | Mar 31, 2026 | -23.25 | -23.98 | -0.73 | -3.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | JP Morgan | init | — | Overweight |
| Oct 12, 2026 | Rodman & Renshaw | init | — | Buy |
| Aug 12, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 13, 2026 | Jefferies | main | Buy | Buy |
| Jul 13, 2026 | Wedbush | main | Outperform | Outperform |
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hemab.com
News
Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting 
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition 
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026 
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 - Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket 
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64 
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60 - Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate
- Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 Congress
Your note
Sign in to keep a note on COAG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MARAGANORE JOHN M | Director | Conversion of Exercise of derivative security | May 3, 2026 | 35,948 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 3, 2026 | 4,180,550 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 11, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 15, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 16.72% | 7,808,627 | 382.78M | Jun 29, 2026 |
| Novo Holdings A/S | 8.95% | 4,180,550 | 204.93M | Jun 29, 2026 |
| FMR, LLC | 7.92% | 3,697,837 | 181.27M | Jun 29, 2026 |
| Capital International Investors | 7.72% | 3,603,876 | 176.66M | Jun 29, 2026 |
| Deep Track Capital, Lp | 7.71% | 3,602,093 | 176.57M | Jun 29, 2026 |
| Siren, L.L.C. | 4.47% | 2,086,834 | 102.30M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.51% | 3,506,543 | 171.89M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.19% | 555,543 | 27.23M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 1.14% | 531,382 | 26.05M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.12% | 523,853 | 25.68M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.10% | 514,858 | 25.24M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.08% | 506,791 | 24.84M | Sep 29, 2026 |